Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus nivolumab alone in advanced or metastatic TMB-high solid tumors
NL-OMON52919Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Nonhematologic neoplasms and Metastatic solid neoplasm comparing Nivolumab + ipilimumab with Nivolumab monotherapy (2 arms). Primary endpoints: BICR-assessed objective response rate in tTMB-high participants treated with nivolumab plus ipilimumab and BICR-assessed objective response rate in bTMB-high participants treated with nivolumab plus ipilimumab. Started Jan 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Nonhematologic neoplasmsMetastatic solid neoplasm
Beyond the preview
Go deeper on NL-OMON52919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52919.